By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Shire 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Amicus Therapeutics, Inc. 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Sanofi 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. ORPHAZYME A/S 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Avrobio, Inc. 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. JCR Pharmaceutical Co. Ltd. 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Lixte Biotechnology Holdings, Inc. 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Pharming Group NV 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Adienne Pharma and Biotech 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Greenovation Biopharmaceuticals 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT List of Tables List of Figures * There may be changes in final report as per data availability.